Research Topics
| Simona Di GiambenedettoSummaryAffiliation: Catholic University Country: Italy Publications
| Collaborators
|
Detail Information
Publications
Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA)Antonella Cingolani
Istituto di Clinica delle Malattie Infettive, , Largo Agostino Gemelli 8, 00168 Rome, Italy
AIDS 16:369-79. 2002..CONCLUSION: The virological benefit of genotype-guided treatment decisions in heavily pre-exposed patients was short term. Patients adherence and residual treatment options influenced outcomes...- Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort studyS Di Giambenedetto
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Infection 37:438-44. 2009..We explored the efficacy of at least 16 weeks of ABC + TDF-containing cART regimens in 307 antiretroviral-experienced HIV-1-infected individuals included in observational databases... - Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort studySimona Di Giambenedetto
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 12:835-9. 2007..We explored the evolution of genotypic drug resistance prevalence in treatment-failing patients from 1999 to 2005 in a clinical cohort... - Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009S Di Giambenedetto
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Clin Microbiol Infect 17:1352-5. 2011..Independent predictors of three-class resistance were the number of treatment regimens experienced, prior suboptimal nucleoside reverse transcriptase inhibitor therapy and the current use of ritonavir-boosted protease inhibitors... - Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in ItalySimona Di Giambenedetto
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 14:359-69. 2009..This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA)... - Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictorsSimona Di Giambenedetto
Institute of Clinical Infectious DiseasesCatholic University, Rome, Italy
Scand J Infect Dis 39:813-8. 2007..In patients failing PIs, the interpretation of genotypic resistance to fosamprenavir may change considerably according to the different algorithms and in respect to the effect of pharmacokinetic boosting with ritonavir... - Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomesAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 9:583-93. 2004.... - Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1Laura Bracciale
Institute of Clinical of Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
AIDS Res Hum Retroviruses 25:261-7. 2009..The achievement of virological suppression is a strong predictor of reduced clinical progression... - Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparisonAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
Antivir Ther 11:609-18. 2006..A multi-cohort prospective observational comparative study was performed... - Three-year clinical outcomes of resistance genotyping and expert advice: extended follow-up of the Argenta trialAndrea De Luca
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
Antivir Ther 11:321-7. 2006.... - Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new scoreAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 16:489-97. 2011..There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score... - Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?Laura Bracciale
Institute of Clinical Infectious Disease, Catholic University of Sacred Heart, Rome, Italy
Antivir Ther 14:99-101. 2009.... - Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapyAndrea De Luca
Clinical Infectious Diseases, Catholic University, Rome, Italy
J Infect Dis 193:1219-22. 2006..42 [95% CI, 1.05-1.99]), use of nevirapine (adjusted OR, 1.60 [95% CI, 1.14-2.24]), use of efavirenz (adjusted OR, 1.56 [95% CI, 1.08-2.27]), and use of ritonavir (adjusted OR, 1.35 [95% CI, 1.04-1.75])... - Deep salvage with amprenavir and lopinavir/ritonavir: correlation of pharmacokinetics and drug resistance with pharmacodynamicsAndrea De Luca
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Rome, Italy
J Acquir Immune Defic Syndr 35:359-66. 2004..When these drugs are coadministered, therapeutic drug monitoring should be employed and the IQ can be used to determine target drug levels... - Association of HIV-1 replication capacity with treatment outcomes in patients with virologic treatment failureAndrea De Luca
Institute of Clinical Infectious Diseases, Policlinoco Universitario Agostino Gemelli, Catholic University of the Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
J Acquir Immune Defic Syndr 45:411-7. 2007..The extent to which HIV-1 replication capacity (RC) influences the response to therapy remains to be established... - Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practiceMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
J Med Virol 82:1996-2003. 2010..Despite the likely differences in patient population and adherence, both the low rate of virological failure and the lack of development of LPV/rtv resistance documented in clinical trials are thus confirmed in clinical practice... - Interpretation systems for genotypic drug resistance of HIV-1Andrea De Luca
Istituto di Clinica delle Malattie Infettive, , Rome, Italy
Scand J Infect Dis Suppl 35:29-34. 2003..Importantly, only 8 systems were intended for clinical use and 5 of these had at least partially undergone clinical validation... - Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotypingMattia C F Prosperi
Infectious Diseases Clinic, Catholic University of Sacred Heart, Rome, Italy
Retrovirology 7:56. 2010..7% false positive rate cutoff were evaluated using viral DNA and RNA samples, compared against each other and ESTA, using Cohen's kappa, phylogenetic analysis, and area under the receiver operating characteristic (AUROC)... - Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systemsAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
Antivir Ther 9:743-52. 2004..This work was presented in part at the First European Workshop on HIV Drug Resistance. Luxembourg, 4-6 March 2003 (Abstract 44); and at the 9th European Conference on CIinical AIDS Therapy. Warsaw, 25-28 October 2003 (Abstract F6/7)... - A prognostic model for estimating the time to virologic failure in HIV-1 infected patients undergoing a new combination antiretroviral therapy regimenMattia C F Prosperi
Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
BMC Med Inform Decis Mak 11:40. 2011..However, their relative-hazard for the time to virologic failure has not been thoroughly investigated, and an expert system that is able to predict how long a new cART regimen will remain effective has never been designed... - Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort studyMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
J Antimicrob Chemother 66:1886-96. 2011.... - Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practiceMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Antimicrob Chemother 64:109-17. 2009.... - Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interactionMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
Pharmacol Res 63:249-53. 2011..In conclusion, a potential drug interaction between darunavir and raltegravir was observed, although this did not seem virologically significant. For the distinct metabolic pathways of these drugs, its mechanism remains to be determined... - The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapyAngela Marzocchetti
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
AIDS Res Hum Retroviruses 27:1299-309. 2011..10; p=0.04). Knowledge of the effect of genetic determinants on dyslipidemia and lipodystrophy may prompt the investigation of potential pathogenetic mechanisms and might eventually be used for guiding individualized treatment decisions... - Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistanceAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Infect Dis 187:1934-43. 2003..GSSs predicted changes in HIV RNA levels better in adherent patients than in nonadherent individuals. Interpretation may be improved, and knowledge should be used uniformly throughout different expert systems... - Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysisAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Lazio Region, Rome, Italy
AIDS 22:1759-67. 2008..To establish the effectiveness of cidofovir for AIDS-related progressive multifocal leukoencephalopathy (PML) in patients concomitantly receiving combination antiretroviral therapy... - The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispeciesMattia C F Prosperi
Infectious Diseases Clinic, Catholic University of the Sacred Heart, Rome, Italy
PLoS ONE 5:e13619. 2010..We introduce the threshold bootstrap clustering (TBC), a new methodology for partitioning molecular sequences, that does not require a phylogenetic tree estimation... - Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapyAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University, Rome, Italy
J Acquir Immune Defic Syndr 59:113-20. 2012..63, P = 0.11; cause-specific aRR 5.27, P = 0.019) than those with haplogroup H. Mitochondrial haplogroups may explain part of the genetic predisposition to lipodystrophy during combination antiretroviral therapy... - Liver fibrosis stage predicts early treatment outcomes with peginterferon plus ribavirin in HIV/hepatitis C virus co-infected patientsAndrea De Luca
Institute of Clinical Infectious Diseases, Catholic University of of Sacred Heart, Rome, Italy
AIDS 18:1602-4. 2004..Female sex and HCV genotype predicted early virological responses. Results support the early treatment of HCV in co-infected individuals... - Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutationMauro Zaccarelli
National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy
Antivir Ther 8:51-6. 2003..M184V/I mutation is associated with high-level phenotypic resistance to lamivudine (3TC). The aim of the present analysis was to correlate the time of appearance/disappearance of M184V/I with duration of 3TC treatment... - A novel methodology for large-scale phylogeny partitionMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of the Sacred Heart, Rome, Italy
Nat Commun 2:321. 2011..Our method takes an advantage of a flexible notion of transmission cluster and can become a general framework to analyse other epidemics... - Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCRCinzia Dello Russo
Institute of Pharmacology, Catholic University Medical School, Rome, Italy
Pharmacogenomics 12:567-76. 2011..A fast, sensitive and specific test for HLA-B*57:01 detection has been developed in the present study... - Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patientsMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Largo F Vito 1, 00168 Rome, Italy
Vaccine 29:2836-9. 2011..These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients... - Coccidioidomycosis of cervical lymph nodes in an HIV-infected patient with immunologic reconstitution on potent HAART: a rare observation in a nonendemic areaAlessandro D'Avino
Institute of Clinical Infectious Diseases, Catholic University of the Sacred Heart, L go F Vito 1, 00168 Rome, Italy
Diagn Microbiol Infect Dis 72:185-7. 2012.... - Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based modelsMattia C F Prosperi
Clinic of Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
PLoS ONE 5:e13753. 2010..Since treatment history (TH) impacts response to subsequent therapy, we investigated a set of statistical learning models to optimise cART in the absence of GRT information... - Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in ItalyMassimiliano Fabbiani
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
J Med Virol 83:2057-65. 2011..Such findings might contribute to improve clinical and epidemiological management of the disease... - CD4 cell-monitored treatment interruption in patients with a CD4 cell count > 500 x 106 cells/lCristina Mussini
Clinic of Infectious and Tropical Diseases, Azienda Ospedaliero Universitaria Policlinico, University of Modena and Reggio Emilia, Via del Pozzo, 71, 41100 Modena, Italy
AIDS 19:287-94. 2005..Little is known about CD4 cell count changes in patients with high CD4 cell counts who interrupt antiretroviral therapy, especially in those with a nadir of 250-350 x 10 cells/l... - Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapyLaura Aian Gillini
J Acquir Immune Defic Syndr 29:546-7. 2002 - Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failureAndrea Antinori
Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani, IRCCS, 00149 Rome, Italy
AIDS Res Hum Retroviruses 18:835-8. 2002..No virological response was observed in six patients harboring a single Y181C/I mutation. On the basis of the present data, sequential use of NNRTIs should be avoided in the management of treatment failure... - Adherence and plasma drug concentrations are predictors of confirmed virologic response after 24-week salvage highly active antiretroviral therapyEugenia Quiros Roldan
Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
AIDS Patient Care STDS 21:92-9. 2007..4; 95% CI 0.2-0.8; p = 0.014) were both negative independent predictors of sustained virologic response, while the use of boosted protease inhibitor-containing regimens resulted to be protective (OR: 2.4; 95% CI 1.1-5.3; p = 0.032)... - Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patientsCarlo Torti
Institute for Infectious and Tropical Diseases, University of Brescia, p le Spedali Civili 1, 25123 Brescia, Italy
Int J Antimicrob Agents 29:185-90. 2007..The presence of HCV and/or HBV co-infections correlated with higher plasma drug concentrations, although it did not appear to influence hepatotoxicity risk... - Lipid abnormalities in HIV-infected patients are not correlated with lopinavir plasma concentrationsCarlo Torti
J Acquir Immune Defic Syndr 35:324-6. 2004 - A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loadsAlessandro Cozzi-Lepri
Department of Primary Care and Population Sciences, Royal Free and University College Medical School, University College London, United Kingdom
J Infect Dis 194:20-8. 2006.... - Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapyAngela Marzocchetti
Istituto di Clinica delle Malattie Infettive, Universita Cattolica del Sacro Cuore, Largo Gemelli, 8, 00168 Rome, Italy
J Clin Microbiol 43:4175-7. 2005..5% (95% confidence intervals of 42.1 to 72.9%) in the HAART era; the specificity remained unchanged. Predictors of failure to detect JCV DNA were exposure to HAART at disease onset and higher CD4 counts... - A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted RegiCarlo Torti
Institute for Infectious and Tropical Diseases, Brescia, Italy
Clin Infect Dis 40:1828-36. 2005.... - Triple-nucleoside regimens versus efavirenzAndrea De Luca
N Engl J Med 351:717-9; author reply 717-9. 2004 - The influence of hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1-infected patients after initiation of highly active antiretroviral therapySimona Di Giambenedetto
J Acquir Immune Defic Syndr 36:641-2. 2004